India, China Seen Biggest Beneficiaries Of Global 'Patent Cliff'
This article was originally published in PharmAsia News
Executive Summary
India's and China's markets are expected to be among the biggest beneficiaries of the coming flood of branded drugs losing patent protections, IMS Health says